A shake-up may be brewing in the market for GLP-1 diet drugs Friday, and it's making itself felt all across the field of ...

Novo Nordisk A/S’s blockbuster drug Wegovy was targeted for price cuts by the US government and suffered a setback in a new ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...

Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...

Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.

Novo Nordisk (NVO) stock slipped after ate-stage trial data for a higher-dose version of its popular obesity therapy, ...

After Novo Nordisk (NVO) reported results from its Phase 3b STEP UP trial, which showed that adults with obesity achieved a 20.7% weight loss ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

It’s taken LVMH nearly a year-and-a-half to regain its spot as Europe’s biggest stock from Novo Nordisk A/S.